| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.009 |
| mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | 0.096 | 0.01 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | -0.084 | 0.01 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.01 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.088 | 0.01 |
| mRNA | CP724714 | GDSC1000 | pan-cancer | AAC | 0.084 | 0.01 |
| mRNA | AT7867 | CTRPv2 | pan-cancer | AAC | 0.09 | 0.01 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.079 | 0.01 |
| mRNA | GSK690693 | GDSC1000 | pan-cancer | AAC | 0.078 | 0.01 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | 0.085 | 0.01 |